The second session investigated nanoparticles and their potential for diagnosing and treating diseases of the brain and central nervous system. The second keynote speech of the day, "Imaging the Addicted Brain," given by Nora Volkow, M.D., director of the National Institute on Drug Abuse/NIH, Bethesda, Md., discussed the role of molecular imaging in the cutting edge research now underway to elucidate the biology of addiction.
During the sessions that took place in the afternoon, the focus shifted to more selected topics, such as those addressing the evolving areas of blood-brain barrier delivery and cellular therapies for treating brain tumors. For example, the third session covered successes and challenges in crossing the blood-brain barrier to deliver imaging and therapeutic agents. The final session of the day explored stem cell therapeutics and adoptive immunotherapies for brain tumors.
"It is increasingly important to find and implement new ways of studying the brain," said MICoE President Henry F. VanBrocklin, Ph.D., professor of radiology and director of radiopharmaceutical research in the Center for Functional and Molecular Imaging at the University of California, San Francisco, and a member of the symposium's program committee. "Molecular imaging can improve our understanding and management of critical central nervous system pathophysiological processes, such as neurodegeneration, brain tumors and psychiatric diseases."
This evening, a banquet and abstracts award presentation will recognize research by some of the outstanding new researchers in the field. Michael Phelps, Ph.D., University of California, Los Angeles, will speak at the dinner and focus on translating metabo
|Contact: Amy Shaw|
Society of Nuclear Medicine